The Dynamics of Frailty in Older People

December 18, 2020 updated by: University of Southampton

The Dynamics of Frailty in Older People: Modelling Impact on Health Care Demand and Outcomes to Inform Service Planning and Commissioning

In the context of reduced resources and rising demand for unplanned care, the delivery of appropriate services to support people with frailty will be key to providing cost-effective, quality care for older people. There is recognition of an evidence gap in relation to the planning, commissioning and delivery of services for older people living with frailty. Questions remain about the incidence and prevalence different levels of frailty and the consequences for health outcomes, health and care service use and costs.

In this study, the investigators will explore the incidence and prevalence, development and impact of frailty within the population using retrospective primary care data on patients aged 50 and over in 2006 within the database. The investigators will stratify the cohort by severity of frailty and explore frailty status over time, determining incidence, prevalence and progression of frailty. The relationships between factors such as age, deprivation, ethnicity, location and comorbidities of individuals in relation to development of, and deterioration in, frailty status will be examined. The influence of frailty on outcomes, service use and costs will be explored. These analyses will be used to inform the development of a prototype simulation model, which will use a System Dynamics (SD) based approach to explore the development and impact of frailty in the population and likely future scenarios over a 10-year timeframe. Finally, 'what if' scenarios developed with the stakeholder engagement group will be explored via simulation modelling.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

The impact of frailty on demand for and outcomes of care has emerged as a significant issue for the National Health Service (NHS) in recent years. The association between frailty and adverse outcomes such as unplanned admission, transfer to residential care and high service use is well recognised (BGS 2014/15; NIHR 2017; Clegg et al. 2013). As the population ages, prevalence of frailty and associated demand for health care rise. In the context of reduced resources and rising demand for unplanned care, the delivery of appropriate services to support people with frailty will be key to providing cost-effective, quality care for older people. Recent consensus guidelines have emphasised the importance of identification and clinical management of frailty (BGS 2014; NICE 2016) and effective interventions are available, but capacity and resources for delivery are limited. There is recognition of an evidence gap in relation to the planning, commissioning and delivery of services for older people living with frailty (NIHR 2017). Questions remain about the incidence and prevalence different levels of frailty and the consequences for health outcomes, health and care service use and costs. Addressing these issues requires exploration of population trends in the development and impact of frailty, but this research has previously been limited because of the need for clinical assessment for the identification of frailty. The recent introduction of the electronic Frailty Index (eFI) (Clegg et al. 2016) allows routine primary care data to be used to identify the presence and severity of frailty in real-world populations. The eFI therefore facilitates the exploration of the dynamics of frailty and its impact at a population level. It enables stratification of the primary care population into robust, mild, moderate and severe frailty groups, so enabling comparison of trajectories of decline and pathways of care between these groups, which will be key to service development and commissioning.

In this study, the investigators will explore the incidence and prevalence, development and impact of frailty within the population using retrospective data from the Royal College of General Practitioners Research Surveillance Centre (RCGP RSC) database, which holds data for 1.8m patients from 230 practices. The eFI tool will be utilised to stratify a cohort of people aged 60 and over within the database between 2004-8 into robust, mild, moderate and severe frailty groups. Data will be extracted on frailty status, health care use, and outcomes for the subsequent 10 years, calculating key service use costs from these data. Outcomes will include mortality, unplanned hospital admission, Accident and Emergency (A&E) attendance and General Practitioner (GP) appointments. The RCGP RSC dataset will also provide data on socio-economic factors, practice size and location and residence. The cohort will be stratified by severity of frailty, and frailty status explored over time, determining incidence, prevalence and progression of frailty. The investigators will examine the relationships between factors such as age, deprivation, ethnicity, location and comorbidities of individuals in relation to development of, and deterioration in, frailty status. The influence of frailty on outcomes, service use and costs will be explored. Results from these analyses will be used to inform development of guidelines for service commissioners, developed in partnership with experts in service delivery, commissioning and Public Patient Involvement (PPI) representatives through stakeholder engagement. These analyses will inform the development of a prototype simulation model, which will use a System Dynamics (SD) based approach to explore the development and impact of frailty in the population and likely future scenarios over a 10-year timeframe. The simulation model population projections will be externally validated against retrospective data from the Leeds Data Model (LDM) dataset, which holds data for 810,000 primary care patients from 108 practices in the Leeds area. Residence data from RCGP RSC will be supplemented by data on residential care transitions and social care use by frailty status from the Secure Anonymised Information Linkage (SAIL) Databank, which holds primary and social care data on up to 30,000 individuals in Wales, to inform simulation of impacts and costs beyond the health care setting. Finally, 'what if' scenarios developed with the stakeholder engagement group (SEG) will be explored via simulation modelling.

Study Type

Observational

Enrollment (Anticipated)

300000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hampshire
      • Southampton, Hampshire, United Kingdom, SO17 1BJ
        • Recruiting
        • University of Southampton
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Retrospective primary care patient population aged 50 and over in 2006

Description

Inclusion Criteria:

  • aged 50 years and above
  • registered with participating GP practices between 2006 and 2016

Exclusion Criteria:

• aged less than 50 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
electronic Frailty index
Time Frame: 10 years
Incidence of frailty
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: 10 years
Deaths
10 years
Service use
Time Frame: 10 years
use of Emergency Department (ED) and primary care services
10 years
cost of GP visit, ED attendance, hospital admission etc
Time Frame: 10 years
Costs of primary and secondary care services
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bronagh Walsh, PhD, University of Southampton

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 21, 2020

Primary Completion (ANTICIPATED)

February 28, 2022

Study Completion (ANTICIPATED)

February 28, 2022

Study Registration Dates

First Submitted

July 29, 2019

First Submitted That Met QC Criteria

October 22, 2019

First Posted (ACTUAL)

October 25, 2019

Study Record Updates

Last Update Posted (ACTUAL)

December 21, 2020

Last Update Submitted That Met QC Criteria

December 18, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HS&DR16/116/43

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share individual participant data (IPD) with other researchers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frail Elderly Syndrome

Clinical Trials on Observational

3
Subscribe